Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.

Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.

Abstract: Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or more polymorphism sites in linkage disequilibrium thereto, selected from one or more of the following: rs2069910; rs2069916; rs2069924; rs2069931; rs1799808; rs2069920; and rs6714364 and may further involve comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response to treatment with activated protein C or protein C-like compound or correspond to susceptibility to major organ dysfunction or susceptibility to an inflammatory condition.

Abstract: The present application provides methods, uses, commercial packages, and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition and for identifying subjects having a greater benefit from treatment with an anti-inflammatory agent or an anti-coagulant agent. The method generally includes determining the genotype at position rs7222094 or a polymorphic site in linkage disequilibrium thereto for a subject for a polymorphisms in the these genes. The application also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and to recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.

Abstract: The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a Plasminogen Activator Inhibitor-1 (PAI-1) genotype of a patient for one or more polymorphisms in the PAI-1 gene of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. PAI-1 genotype screening may be useful in identifying patients who would benefit from increased monitoring by healthcare professionals, and/or possible therapeutic intervention, if the patient were to develop inflammation due to systemic inflammation response syndrome (SIRS), bacterial infection, bacteraemia, sepsis, septic shock, organ dysfunction, and trauma.

Abstract: The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises determining a protein C pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response polymorphism to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with activated protein C or protein C like compound and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.

Abstract: The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a protein C promoter genotype of a patient for a polymorphism in the protein C promoter region of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition.

Abstract: The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a protein C promoter genotype of a patient for a polymorphism in the protein C promoter region of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition.

Abstract: Methods, oligonucleotides arrays etc. for treating inflammatory conditions and of predicting subject outcome based on polymorphisms in SERPINE1 and/or PROC, alone or in combination, wherein the method of treatment includes administering to the subject an anti-inflammatory agent or an anti-coagulant agent, wherein said subject is determined to have an improved response genotype or combination.

Abstract: The invention provides methods, nucleic acids, compositions and kits for predicting a subject's outcome with an inflammatory condition and a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises determining a interferon gamma (IFNG) gene polymorphism genotype(s) of a subject for one or more polymorphisms in the IFNG gene or associated sequence, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response polymorphism to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with activated protein C or protein C like compound and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.

Abstract: The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with one or more vasopressin receptor agonists to identify subjects having a greater benefit from treatment with vasopressin receptor agonist(s). The method generally comprises determining a vasopressin pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response genotype to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with a vasopressin receptor agonist and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with vasopressin receptor agonists based on the subject's genotype.

Abstract: The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition and or a gram positive infection. The method generally includes determining a toll-like receptor 2 (TLR-2) risk genotype of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis.

Abstract: The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition or hypertension. The method generally comprises determining a coagulation factor III genotype(s) of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis. The invention also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.